The roles of kinases in familial Parkinson's disease
- PMID: 17978026
- PMCID: PMC6673380
- DOI: 10.1523/JNEUROSCI.3695-07.2007
The roles of kinases in familial Parkinson's disease
Abstract
The purpose of this mini-symposium is to discuss some of the inherited forms of Parkinson's disease (PD) in view of recent data suggesting that some of the proteins affect cellular signaling pathways. As an illustration, we shall focus on two different kinases associated with recessive and dominant forms of PD. Mutations in the mitochondrial kinase PTEN (phosphatase and tensin homolog)-induced kinase 1 (PINK1) are loss-of-function mutations in a normally neuroprotective protein. Loss-of-function mutations in model organisms have variable effects, from dramatic muscle and spermatid defects in Drosophila to more subtle neurophysiological abnormalities in mice. Several lines of evidence relate these to the action of a second gene for familial PD, parkin, an E3 ubiquitin ligase shown recently to have effects on Akt signaling. Mutations in leucine-rich repeat kinase 2 (LRRK2), a cytosolic kinase, are dominant and have the opposite effect of causing neuronal damage. The mechanism(s) involved are uncertain at this time because LRRK2 is a large and complex molecule with several domains. Increased kinase activity accounts for the action of at least some of the mutations, suggesting that hyperactive or misregulated kinase activity may lead to the damaging effects of LRRK2 in neurons. For both PINK1 and LRRK2, the following key question that needs to be answered: what are the physiological substrates that mediate effects in cells? Here, we will discuss some of the recent thinking about physiological and pathological roles for signaling in PD and how these may have therapeutic implications for the future.
Similar articles
-
LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.Hum Mol Genet. 2019 May 15;28(10):1645-1660. doi: 10.1093/hmg/ddz004. Hum Mol Genet. 2019. PMID: 30629163
-
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.BMB Rep. 2010 Apr;43(4):233-44. doi: 10.5483/bmbrep.2010.43.4.233. BMB Rep. 2010. PMID: 20423607 Review.
-
A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease.J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):391-5. doi: 10.1136/jnnp.2009.185231. Epub 2009 Sep 2. J Neurol Neurosurg Psychiatry. 2010. PMID: 19726410
-
Kinase signaling dysfunction in Parkinson's disease: a reverse genetic approach in Drosophila.J Neurogenet. 2012 Jun;26(2):158-67. doi: 10.3109/01677063.2012.672499. Epub 2012 Apr 10. J Neurogenet. 2012. PMID: 22486164 Review.
-
Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.Mol Neurobiol. 2016 Oct;53(8):5161-77. doi: 10.1007/s12035-015-9435-4. Epub 2015 Sep 23. Mol Neurobiol. 2016. PMID: 26399642 Free PMC article.
Cited by
-
Quantitative phosphoproteomic profiling of PINK1-deficient cells identifies phosphorylation changes in nuclear proteins.Mol Biosyst. 2014 Jul;10(7):1719-29. doi: 10.1039/c3mb70565j. Epub 2014 Mar 13. Mol Biosyst. 2014. PMID: 24626860 Free PMC article.
-
alpha-synuclein and LRRK2: partners in crime.Neuron. 2009 Dec 24;64(6):771-3. doi: 10.1016/j.neuron.2009.12.017. Neuron. 2009. PMID: 20064381 Free PMC article.
-
Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.Biochemistry. 2013 Mar 12;52(10):1725-36. doi: 10.1021/bi3012077. Epub 2013 Mar 1. Biochemistry. 2013. PMID: 23379419 Free PMC article.
-
LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.Neurobiol Dis. 2010 Oct;40(1):73-81. doi: 10.1016/j.nbd.2010.04.002. Epub 2010 Apr 9. Neurobiol Dis. 2010. PMID: 20382224 Free PMC article.
-
Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.Methods Mol Biol. 2012;795:45-54. doi: 10.1007/978-1-61779-337-0_3. Methods Mol Biol. 2012. PMID: 21960214 Free PMC article.
References
-
- Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem Res. 2007;32:1700–1708. - PubMed
-
- Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441:1162–1166. - PubMed
-
- Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet. 2006;15:223–232. - PubMed
-
- Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem. 2003;278:43628–43635. - PubMed
-
- Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 2006;23:329–341. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials